Atacicept

• CAT Number: I042169
• CAS Number: 845264-92-8
• Purity: ≥95%

Atacicept (Cat No.: I042169) is a recombinant fusion protein that inhibits the activity of B-cell activating factors, specifically BAFF (B-lymphocyte stimulator) and APRIL (a proliferation-inducing ligand). By binding these ligands, Atacicept reduces the survival and function of B cells and plasma cells, offering therapeutic potential in autoimmune diseases like systemic lupus erythematosus and multiple sclerosis. It helps control abnormal immune responses and antibody production. Atacicept’s targeted mechanism makes it a promising candidate for treating B cell–mediated disorders and related inflammatory conditions.

Reference

[1]. Gross JA, et, al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS. Immunity. 2001 Aug;15(2):289-302.
[Content Brief]

[2]. Gross JA, et, al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000 Apr 27;404(6781):995-9.
[Content Brief]